Drug
Fadraciclib
Fadraciclib is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
25%
Ph phase_1
3
75%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
3(75.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
Suspended1
Recruiting1
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (25.0%)
Phase 13 (75.0%)
Trials by Status
suspended125%
recruiting125%
completed125%
unknown125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_1
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT02813135
completedearly_phase_1
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
NCT05817890
suspendedphase_1
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
NCT05168904
unknownphase_1
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
NCT04983810
Clinical Trials (4)
Showing 4 of 4 trials
NCT02813135Phase 1
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT05817890Early Phase 1
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
NCT05168904Phase 1
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
NCT04983810Phase 1
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4